PP263—Importance of TDM, phenotyping and genotyping during intoxication with venlafaxine

Abstract

e100 Volume 35 Number 8S generic risperidone, although there were prescribing restrictions for long-acting injectable risperidone in Austria and Belgium. As a result, no change in its utilization after generics reimbursed. Overall, high utilization of generic versus originator risperidone once available. Appreciable reduction in the price of generic risperidone once it became available limited the extent of any subsequent increase in AAP expenditure despite increasing utilization. Conclusion: No apparent effectiveness or safety problems with generic risperidone. Authorities cannot rely on a spillover effect from other disease areas to change physician prescribing habits, exacerbated on this occasion by the need to tailor treatment approaches with different AAPs having different mechanisms of action and appreciable variability in their effectiveness and side-effects between patients Consequently, specific demand-side measures are needed to encourage the prescribing of generic AAPs first line where appropriate, exacerbated by the complexity of these disease areas. Likely in any event that there will be limited influence of any measures in changing subsequent physician prescribing habits when managing patients with schizophrenia or BPD compared with acid-related stomach disorders or hypercholesterolemia as a greater need to tailor treatments. Generally no specific measures planned by these authorities to influence future prescribing habits with further generic AAPs becoming available. Financial Source: Study part funded by a grant from the Karolinska Institutet. Majority of authors employed by health authorities or are advisers to them. Disclosure of Interest: None declared.